Lexeo Therapeutics Common Net Income
| LXEO Stock | 7.16 0.27 3.92% |
As of the 8th of February, Lexeo Therapeutics secures the Standard Deviation of 5.03, risk adjusted performance of (0.03), and Mean Deviation of 3.47. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Lexeo Therapeutics Common, as well as the relationship between them.
Lexeo Therapeutics Total Revenue |
|
| Last Reported | Projected for Next Year | ||
| Net Loss | -88.5 M | -92.9 M | |
| Net Loss | -88.5 M | -92.9 M | |
| Net Loss | (3.56) | (3.74) |
Lexeo | Net Income | Build AI portfolio with Lexeo Stock |
Evaluating Lexeo Therapeutics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Lexeo Therapeutics Common's fundamental strength.
Latest Lexeo Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Lexeo Therapeutics Common over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Lexeo Therapeutics Common financial statement analysis. It represents the amount of money remaining after all of Lexeo Therapeutics Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Lexeo Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lexeo Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (98.33 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Lexeo Net Income Regression Statistics
| Arithmetic Mean | (30,160,650) | |
| Coefficient Of Variation | (121.40) | |
| Mean Deviation | 32,363,116 | |
| Median | (5,152,788) | |
| Standard Deviation | 36,613,562 | |
| Sample Variance | 1340.6T | |
| Range | 93.2M | |
| R-Value | (0.85) | |
| Mean Square Error | 405.6T | |
| R-Squared | 0.72 | |
| Significance | 0.000018 | |
| Slope | (6,136,753) | |
| Total Sum of Squares | 21448.8T |
Lexeo Net Income History
Other Fundumenentals of Lexeo Therapeutics Common
Lexeo Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Lexeo Therapeutics is extremely important. It helps to project a fair market value of Lexeo Stock properly, considering its historical fundamentals such as Net Income. Since Lexeo Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lexeo Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lexeo Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Lexeo diversify its offerings? Factors like these will boost the valuation of Lexeo Therapeutics. Expected growth trajectory for Lexeo significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Lexeo Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Lexeo Therapeutics Common using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Lexeo Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Lexeo Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Lexeo Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lexeo Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Lexeo Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Lexeo Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Lexeo Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Lexeo Therapeutics.
| 11/10/2025 |
| 02/08/2026 |
If you would invest 0.00 in Lexeo Therapeutics on November 10, 2025 and sell it all today you would earn a total of 0.00 from holding Lexeo Therapeutics Common or generate 0.0% return on investment in Lexeo Therapeutics over 90 days. Lexeo Therapeutics is related to or competes with Kyverna Therapeutics, Contineum Therapeutics, Silence Therapeutics, Larimar Therapeutics, Capricor Therapeutics, Mereo BioPharma, and Voyager Therapeutics. Lexeo Therapeutics is entity of United States More
Lexeo Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Lexeo Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Lexeo Therapeutics Common upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 34.26 | |||
| Value At Risk | (7.63) | |||
| Potential Upside | 7.04 |
Lexeo Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lexeo Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Lexeo Therapeutics' standard deviation. In reality, there are many statistical measures that can use Lexeo Therapeutics historical prices to predict the future Lexeo Therapeutics' volatility.| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.35) | |||
| Total Risk Alpha | (0.73) | |||
| Treynor Ratio | (0.16) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Lexeo Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Lexeo Therapeutics February 8, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.15) | |||
| Mean Deviation | 3.47 | |||
| Coefficient Of Variation | (2,266) | |||
| Standard Deviation | 5.03 | |||
| Variance | 25.26 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.35) | |||
| Total Risk Alpha | (0.73) | |||
| Treynor Ratio | (0.16) | |||
| Maximum Drawdown | 34.26 | |||
| Value At Risk | (7.63) | |||
| Potential Upside | 7.04 | |||
| Skewness | (1.18) | |||
| Kurtosis | 5.72 |
Lexeo Therapeutics Common Backtested Returns
Lexeo Therapeutics Common has Sharpe Ratio of -0.0294, which conveys that the firm had a -0.0294 % return per unit of risk over the last 3 months. Lexeo Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Lexeo Therapeutics' Risk Adjusted Performance of (0.03), standard deviation of 5.03, and Mean Deviation of 3.47 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 1.46, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Lexeo Therapeutics will likely underperform. At this point, Lexeo Therapeutics Common has a negative expected return of -0.15%. Please make sure to verify Lexeo Therapeutics' potential upside, rate of daily change, as well as the relationship between the Rate Of Daily Change and period momentum indicator , to decide if Lexeo Therapeutics Common performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.47 |
Modest reverse predictability
Lexeo Therapeutics Common has modest reverse predictability. Overlapping area represents the amount of predictability between Lexeo Therapeutics time series from 10th of November 2025 to 25th of December 2025 and 25th of December 2025 to 8th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Lexeo Therapeutics Common price movement. The serial correlation of -0.47 indicates that about 47.0% of current Lexeo Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.47 | |
| Spearman Rank Test | -0.54 | |
| Residual Average | 0.0 | |
| Price Variance | 1.4 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Lexeo Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Lexeo Therapeutics Common reported net income of (98.33 Million). This is 128.81% lower than that of the Biotechnology sector and 240.38% lower than that of the Health Care industry. The net income for all United States stocks is 117.22% higher than that of the company.
Lexeo Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lexeo Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lexeo Therapeutics could also be used in its relative valuation, which is a method of valuing Lexeo Therapeutics by comparing valuation metrics of similar companies.Lexeo Therapeutics is currently under evaluation in net income category among its peers.
Lexeo Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Lexeo Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Lexeo Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Lexeo Fundamentals
| Return On Equity | -0.81 | ||||
| Return On Asset | -0.45 | ||||
| Current Valuation | 407.55 M | ||||
| Shares Outstanding | 72.99 M | ||||
| Shares Owned By Insiders | 0.42 % | ||||
| Shares Owned By Institutions | 91.73 % | ||||
| Number Of Shares Shorted | 11.46 M | ||||
| Price To Book | 4.32 X | ||||
| Gross Profit | (65.95 M) | ||||
| EBITDA | (96.19 M) | ||||
| Net Income | (98.33 M) | ||||
| Total Debt | 9.92 M | ||||
| Book Value Per Share | 2.20 X | ||||
| Cash Flow From Operations | (81.15 M) | ||||
| Short Ratio | 6.45 X | ||||
| Earnings Per Share | (2.50) X | ||||
| Target Price | 19.64 | ||||
| Number Of Employees | 61 | ||||
| Beta | 1.8 | ||||
| Market Capitalization | 522.59 M | ||||
| Total Asset | 146.94 M | ||||
| Retained Earnings | (280.17 M) | ||||
| Working Capital | 103.28 M | ||||
| Net Asset | 146.94 M |
About Lexeo Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lexeo Therapeutics Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lexeo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lexeo Therapeutics Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Lexeo Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lexeo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lexeo Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Lexeo Stock
The ability to find closely correlated positions to Lexeo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lexeo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lexeo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lexeo Therapeutics Common to buy it.
The correlation of Lexeo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lexeo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lexeo Therapeutics Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lexeo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Will Biotechnology sector continue expanding? Could Lexeo diversify its offerings? Factors like these will boost the valuation of Lexeo Therapeutics. Expected growth trajectory for Lexeo significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Lexeo Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Lexeo Therapeutics Common using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Lexeo Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Lexeo Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Lexeo Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lexeo Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Lexeo Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.